| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.292 | 0.923 | 1.00 |
|
group | 0.120 | None | 1.000 | 0 | 0 | 2017 | 2019 | ||||||||
|
catenin beta 1 | 0.303 | 0.885 | 1.00 |
|
group | 0.190 | None | 1.000 | 0 | 0 | 2013 | 2019 | ||||||||
|
phosphatase and tensin homolog | 0.305 | 0.923 | 0.26 |
|
group | 0.450 | None | 1.000 | 0 | 0 | 2001 | 2019 | ||||||||
|
AKT serine/threonine kinase 1 | 0.311 | 0.962 | 0.98 |
|
group | 0.110 | None | 1.000 | 0 | 0 | 2014 | 2014 | ||||||||
|
insulin like growth factor 1 | 0.318 | 0.885 | 0.27 |
|
group | 0.130 | None | 0.667 | 0 | 0 | 2003 | 2018 | ||||||||
|
B-Raf proto-oncogene, serine/threonine kinase | 0.319 | 0.846 | 1.00 |
|
group | 0.110 | None | 0.667 | 0 | 0 | 2006 | 2009 | ||||||||
|
KRAS proto-oncogene, GTPase | 0.320 | 0.923 | 7.9E-04 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
actin beta | 0.325 | 0.923 | 0.99 |
|
group | 0.200 | None | 1.000 | 0 | 0 | 1999 | 2019 | ||||||||
|
mitogen-activated protein kinase 1 | 0.330 | 0.923 | 1.00 |
|
group | 0.110 | None | 1.000 | 0 | 0 | 2018 | 2018 | ||||||||
|
matrix metallopeptidase 2 | 0.333 | 0.923 | 0.84 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
mechanistic target of rapamycin kinase | 0.343 | 0.885 | 1.00 |
|
group | 0.470 | strong | 1.000 | 0 | 0 | 2015 | 2019 | ||||||||
|
brain derived neurotrophic factor | 0.345 | 0.923 | 0.66 |
|
group | 0.500 | None | 1.000 | 0 | 0 | 1994 | 2018 | ||||||||
|
peroxisome proliferator activated receptor gamma | 0.358 | 0.885 | 2.9E-02 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
NLR family pyrin domain containing 3 | 0.361 | 0.962 | 8.1E-04 |
|
group | 0.110 | None | < 0.001 | 0 | 0 | 2007 | 2007 | ||||||||
|
fibroblast growth factor receptor 1 | 0.362 | 0.885 | 1.00 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
tumor protein p63 | 0.362 | 0.769 | 1.00 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
KIT proto-oncogene, receptor tyrosine kinase | 0.366 | 0.808 | 0.98 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
BRCA1 DNA repair associated | 0.367 | 0.923 | 9.2E-29 |
|
group | 0.400 | limited | 0 | 0 | |||||||||||
|
notch receptor 1 | 0.369 | 0.885 | 1.00 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
telomerase reverse transcriptase | 0.374 | 0.846 | 0.99 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
enhancer of zeste 2 polycomb repressive complex 2 subunit | 0.376 | 0.885 | 1.00 |
|
group | 0.130 | None | 1.000 | 0 | 0 | 2017 | 2019 | ||||||||
|
HRas proto-oncogene, GTPase | 0.378 | 0.885 | 8.0E-02 |
|
group | 0.120 | None | 1.000 | 0 | 0 | 1983 | 2015 | ||||||||
|
BRCA2 DNA repair associated | 0.379 | 0.846 | 2.4E-25 |
|
group | 0.100 | None | 0 | 0 | |||||||||||
|
fibroblast growth factor receptor 2 | 0.380 | 0.808 | 1.00 |
|
group | 0.410 | None | 1.000 | 0 | 0 | 2006 | 2012 | ||||||||
|
solute carrier family 2 member 1 | 0.388 | 0.808 | 0.99 |
|
group | 0.650 | strong | 1.000 | 0 | 0 | 2010 | 2017 |